3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based in Berlin, Germany.
As a leader in peptide discovery and optimization, 3BP is developing peptides for innovative applications in human health, including pharmaceutical product candidates, molecular imaging agents, synthetic affinity purification ligands, and in vitro diagnostics.
Company revenues are generated through R&D collaborations with pharmaceutical partners as well as out-licensing of development candidates.
Our in-house R&D projects focus on the identification and development of novel tracers for targeted molecular imaging and radiotherapy, primarily in the field of oncology. For this purpose, we have selected and characterized innovative targets for next-generation cancer diagnostics and therapeutics. Based on the same target binding peptide, we are able to develop both a diagnostic imaging test and a therapeutic agent. This so called “theranostic” approach combined with the availability of next generation isotopes and formulations has the potential to address major unmet medical needs in oncology and to greatly improve patient treatment options.
Moreover, 3BP has a long-term, multi-target research collaboration with Baxter Corp. to develop new treatment options in haemophilia.
The company was founded in 2008 by a team of experts in peptide drug discovery and nuclear medicine from Berlin, Berne and Basel. The renowned founders from the pharmaceutical and biotechnology industries as well as academia combine their expertise in all stages of the drug-discovery process. Through a buyout of Jerini-AG’s R&D assets, the company became operative in late 2009 and is now based in Berlin Adlershof, a well established science park in the southeast of Berlin, near the new airport Berlin-Brandenburg-International (BBI).